Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV48108 in Healthy Volunteers and COPD Patients
NCT02315144Phase 1Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of TV-48108 in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours. Started Apr 2015; status: terminated.
02
Drugs
TV-48108
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02315144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315144.